Thoughts on Healthcare Markets & Technology Podcast

Epizodes

• 
  Part I: Garmin's CIRQA Screenless Band at $200 Detonates the Subscription Wearables Thesis: What WHOOP, Oura & Eight Sleep Must Do When Sensor Hardware Commoditizes 29.07.2026 9min

  Garmin just launched a $200 screenless health band with no subscription. That one decision puts the entire wearable subscription model under structural pressure.The sensor stack inside every biometric band costs $15-25 to build at scale. The subscription was never about hardware. It was about the intelligence layer. Garmin just commoditized both.WHOOP is valued at ~$3B on ~1M paid subs at $239/yr. Oura has sold ~2.5M rings. Both face a buyer pool that is expanding fast but skewing price-sensitive, driven by the Hemsworth and Bryan Johnson effect.The real question is not which band wins. It is whether a subscription can survive when a company with Garmin’s retail shelf space offers equivalent sensors for a one-time fee.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: The Medicare Transaction Facilitator Turns a Negotiated Drug Price Into an Auditable Claim-Level Event: Two MTF Modules, a Seven-Day PDE Feed and the Part B NDC Identity Gap 26.07.2026 10min

  CMS’s draft MTF guidance is the most detailed operational document in the entire IRA drug pricing rollout, and almost everyone is going to misread the 14-day clock.The Medicare Transaction Facilitator is not the payer. It is a data layer. The underlying claim pays the usual way. The MTF identifies eligible events and ships claim-level data to the manufacturer.Two modules: Data Module is mandatory for everyone. Payment Module is optional. You can opt out of the payment switch. You cannot opt out of reporting. That asymmetry is the spine of the whole design.The 14-day clock starts when the MTF sends verified data to the manufacturer. Not when the drug was given. Not when the claim was filed. It is a manufacturer transmission deadline, not a provider receipt guarantee.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: Sometimes Interoperability Is Just a Modifier: CMS’s CY 2027 Imaging Site-Neutral Cut, the Hospital Machine-Readable File, 835 Allowed-Amount Percentiles, and the Contract-Semantics Price 24.07.2026 11min

  CMS proposed a $260M imaging cut for CY 2027. It only works because two characters on a claim line, modifier PO, reliably identify the target setting. That is interoperability doing real work.The cut applies only to noncontrast imaging in APCs 5521-5524 at grandfathered off-campus departments billing PO. Rural sole-community hospitals are exempt. On-campus departments are not touched. Scope matters.The utilization case: volume up 38% and utilization per FFS beneficiary up 67% from 2016-2025, while FFS enrollment fell 17%. CMS pegs 2027 savings at $260M and $8.5B over a decade.The price transparency side of the package is on the same logic. CMS solved file parsing. The 2027 RFI goes after contract meaning: stop-loss clauses, rate tiers, payer identifiers that actually match across hospitals.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: Medicare Wants a Three-Second Claim But Still Owes a Fourteen-Day Wallet: Inside the ClaimsCore Re-Platforming Draft, the MAP Bridge, and Why Sub-Second Adjudication Cannot Pay Providers 21.07.2026 10min

  CMS wants sub-second Medicare claims adjudication. The statutory payment floor is still 13 days. Those two facts don’t cancel each other. They coexist, and that’s the whole story.The ClaimsCore RFI contemplates replacing FISS, MCS, the DME system, and the Common Working File with a commercial cloud platform. That’s a draft acquisition concept, not an award. Nobody has replaced Medicare’s shared systems.A live bridge, MAP, already runs in limited parallel with the legacy system. Standing it up required preserving continuity with 5 downstream repositories. Even a thin slice of new volume needed every old room to stay reachable.Real-time adjudication and real-time payment are six different claims depending on which transaction type you mean. Only one of them touches your working capital. The 14-day floor is in statute. Congress owns it, not CMS.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: The Jan 2027 Prior Authorization Reckoning: FHIR API Mandates, the Two Year MIPS Attestation Ramp, ONC Certification Gates & Why the Real Money Sits Between the Payer Endpoint and the Order 19.07.2026 8min

  CMS prior auth FHIR APIs are not a proposed rule. They are a January 1, 2027 hard deadline for MA plans, Medicaid managed care, CHIP, and federally facilitated exchange issuers.The decision clocks already went live in 2026: 72 hours for expedited requests, 7 calendar days for standard. Specific denial reasons required. Public reporting of PA metrics started this year.Four APIs due January 2027: Patient Access, Provider Access, Payer-to-Payer, and Prior Authorization. The PA API must accept submissions and return structured approvals, denials with reasons, or info requests.The APIs solve transport. They do not find the clinical evidence in the chart, judge its sufficiency, or fix the request when a payer bounces it. That workflow gap is where the product value actually lives.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: The Scheduled Death of Traditional MIPS: How the CY27 Proposed Rule’s MVP Mandate, Core Measure Trapdoor, QP Threshold Seesaw & FHIR Reporting Clock Reshuffle the Entire Quality Vendor Market 17.07.2026 9min

  Traditional MIPS has a death date. CY 2029 is the cutoff. MVPs become the only reporting option for non-APM clinicians after 2028. Three performance years to rebuild.93% of MIPS reporters earned a positive adjustment in 2017-2019. The largest was 1.88%. Everyone passed, nobody got paid, every practice paid real overhead to get there.The new core measure rule is the sharpest edge. Miss the required core measure without attestation and you get zero out of ten quality points. A ten-point crater at 75-point threshold flips bonuses to penalties.43 of the 180 surviving quality measures change specification in one rule cycle. The AHA walked away from major cardiology measures. Every registry built around those measures owns a migration project now.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: Royalty Pharma for Real World Data: A Royalty Financing Company That Buys Forward Rights to Health System Data Licensing Revenue & Turns Clinical Records Into a Securitizable Asset Class 15.07.2026 10min

  Hospitals are sitting on a recurring, contractual, uncorrelated cash flow buried in ‘other operating revenue.’ Nobody finances it. Nobody prices it. That is the opportunity.It is health system data licensing revenue: deals with pharma, RWE vendors, registries, and now AI labs paying top dollar for clinical text. At big AMCs this runs tens of millions a year, well below potential.The template is Royalty Pharma. Buy forward rights to the stream from institutions that need capital now more than they need checks over 15 years. The spread lives in the modeling gap.Three forces make the timing right: AI training demand just created a new buyer category with new willingness to pay. Infrastructure can now meter the asset. Hospital margins are structurally stressed.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: Rydberg Blockade, Optical Tweezers, and the Long Road to Fault Tolerance: What Neutral Atom Quantum Computing Actually Means for Drug Discovery, Health Data Encryption, and Medical Sensing 13.07.2026 9min

  Neutral atom quantum computers are raising billions. Here is what health systems and pharma boards are not being told about what they can actually do.The Rydberg blockade switches atom interactions from millihertz to hundreds of megahertz with a laser pulse. 11-12 orders of magnitude. That is the gate. That is the whole trick.Gate fidelity is now in the mid-four-nines range with theoretical headroom to five nines. All the remaining gap is engineering: laser noise, atom temperature, stray fields. The physics has room left.Three real buckets for healthcare: quantum chemistry for metalloenzymes (2030s), post-quantum cryptography migration (urgent now, nobody is doing it), and quantum sensing for wearable brain and heart imaging (nearest term). Everything else being pitched is the data loading problem in a suit.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: The Case for a Neutral Healthcare Settlement Exchange That Turns Payer-Provider Contracts Into Executable Code, Guarantees Payment, and Makes Most Denials Structurally Impossible 10.07.2026 5min

  Payers and providers sign one contract. Then each builds separate software to interpret it. Two codebases. Two answers. That gap is where denials live.The industry response: buy better AI. Providers use it to fight denials. Payers use it to generate them. Both sides get better weapons. The battlefield never changes.This is a coordination problem, not a tech problem. Card networks solved it for payments. Central counterparties solved it for securities. Healthcare reimbursement has the same structural signature.The fix is a neutral exchange where both sides pre-approve one executable version of their contract and agree the output is the correct payment. Sell finality, not a better calculator.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: Reading the HHS FY2027 Performance Plan as a Payment Integrity Market Map: Why the Vacated RADV Rule and a $93.5B Improper Payment Pile Separate Incumbent Revenue From Startup Whitespace 09.07.2026 7min

  CMS flagged ~$93.5B in improper payments across 5 programs. A Texas court just vacated the rule designed to claw it back. This is not a compliance story. It is a market structure story.Medicare Advantage hit 6.09% improper payment rate, within target. Sounds fine. But that measure captures documentation gaps, not systematic risk-score inflation worth tens of billions more.RADV was supposed to fix that. The 2023 Final Rule would have turned it into a multibillion-dollar recovery engine. Plans sued. Northern District of Texas vacated key portions on Sept 25, 2025.Here is the insight: litigation that disrupts a mandate multiplies demand for expertise. Both sides now need better statisticians, better sampling, and better chart review than a year ago.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: When the Toolmaker Decides to Also Make the Drugs: Anthropic’s Claude Science Launch, Its In-House Preclinical Bet on Neglected Diseases & What Tool Vs. Competitor Tension Means for Pharma AI 06.07.2026 9min

  Anthropic launched a science research platform AND announced its own drug programs on the same day. The toolmaker opened a mine next to its customers’ mines.Claude Science connects 60-plus scientific databases, runs code on HPC clusters, and keeps data on your own infrastructure. Reproducibility is baked in, every result traces to source code.The conflict: Anthropic sells to pharma and also runs its own preclinical programs. Official answer is they only chase neglected diseases. Disease interest is not static, and that boundary is softer than it sounds.BCG data on AI-discovered molecules: Phase 1 safety jumped to 80-90%. Phase 2 efficacy stayed flat at 40%. The field finds safer drugs. It has not yet found drugs that work at scale.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: 25x the Surgeon’s Pay: How Surgical Assistants Are Using No Surprises Act Arbitration Loopholes to Out Earn the Doctors They Assist in Operating Rooms Nationwide 04.07.2026 11min

  A scoliosis surgery. Surgeon earned $8,016. The assistant standing next to him got $196,566. That is a 24x multiple in favor of the person holding the retractor.It is not a one-off. Texas prostatectomy: surgeon $1,843, assistant $50,456. NJ breast reconstruction: surgeon $2,707, assistant $111,000. Same law, same arbitration channel, same result.The mechanism: No Surprises Act arbitration. Assistants stay out of network on purpose. Arbitrators evaluate their claims in isolation, with no visibility into what the surgeon on the same case collected.One Wisconsin spinal fusion was split into 11 separate arbitration filings. They won all 11. Total payout: ~$196k. Insurer estimate under standard rates: ~$11k. That is unbundling dressed in arbitration clothing.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. For a further deep dive on the topic from today’s video teaser, see the podcast and article link in the comments. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting 02.07.2026 10min

  FDA is formally reviewing BPC-157, TB-500, MOTS-c, Semax, and 3 other gray market peptides at its July 2026 advisory committee meeting. The wellness clinic industry is watching closely.These 7 peptides have no USP monographs, no FDA-approved drug status, and no path to legal 503A compounding until FDA acts. Most were previously in a do-not-compound category. Removal from that list is NOT a green light.Across all 7 substances, FDA’s background documents flag the same problems: weak chemical characterization, no modern human clinical trials, unresolved immunogenicity risk, and manufacturing quality that is largely undocumented.TB-500 is WADA-prohibited. MOTS-c is WADA-prohibited. Semax is approved in Russia under a different standard. BPC-157 is being reviewed for ulcerative colitis, which already has multiple approved therapies. The evidentiary bar is high.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: EchoNext Clears FDA for Six Structural Heart Conditions Off a Standard ECG, Lands on OpenEvidence, and Logs the First AI-Triggered Heart Transplant: Reading the Cardiac Screening Land Grab 30.06.2026 9min

  Pathway Labs cleared the FDA for six structural heart conditions off one ECG. The $8.5M seed round is the least interesting part of this announcement.The model trained on 700k+ ECG-echo pairs at NewYork-Presbyterian. In a 3,200-ECG head-to-head, it hit 77% accuracy vs 64% for cardiologists. That gap is real.Then it landed on OpenEvidence, used by 750k+ verified clinicians. That distribution solves the problem that kills most cardiac AI: getting a busy doctor to actually open the tool.The multicondition framing also quietly ends the single-indication race. Matching six FDA clearances means assembling six evidence packages. Replication cost just went up.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: Why Health Systems Should Build an In-House AI Coding Academy That Teaches Clinicians to Ship Software & Spin Up Companies, Then Keeps a Slice of the Royalties & Equity Their Doctors Generate 28.06.2026 9min

  Hospitals pay vendors 6-7 figures yearly for software a frustrated clinician could have built over a weekend. The clinician usually spec’d it out anyway.Agentic coding tools just flipped the constraint. The gap was never clinical expertise - it was engineering bandwidth. Now that gap is mostly gone.Academic medicine already has the perfect learning model: tumor boards, M&M conferences, grand rounds. An AI coding academy should borrow that, not bootcamp culture.The binding constraint now is ownership and incentives. If the inside deal is a black box, talented clinicians route around it and build outside. The system gets nothing.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: GitHub for Prior Auth: The Most Defensible Health AI Org of the Coding Agent Era Might Not Automate Auth but Version, Test & Distribute the Payer Coverage Rules Everyone Rebuilds From Scratch 26.06.2026 11min

  Every provider org, RCM vendor, and clearinghouse rebuilds the same prior auth logic from the same payer PDFs. In isolation. Every time. That is the infrastructure problem hiding in plain sight.Payer coverage policy is conditional logic: inputs are codes, diagnoses, durations, site of care. Outputs are auth required, document these things first. It behaves like software maintained with no version control.CMS mandates a Prior Authorization API by Jan 1, 2027 for MA, Medicaid, CHIP, and FFE plans. The Da Vinci standards define the pipes. Nobody is building the content layer that makes the rules inside those pipes trustworthy.A vector DB helps someone find a policy paragraph. It does not tell you which version applies today, or whether the rule still does what it did last month. That gap between search and versioned, testable coverage logic is the whole business.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: How Children Learn Once You Subtract Language: Statistical Learning, Causal Intervention, Curiosity & Buildable Healthcare AI Point Solutions Rather Than One Giant World Model 24.06.2026 9min

  Children learn without labels, without feedback, and on almost no data. Healthcare AI still struggles with all three. Here is why the gap is a product opportunity.In 1996, eight-month-olds extracted word boundaries from a two-minute speech stream with no cues except raw statistics. Same machinery works on shapes and tones. It is self-supervised learning on a banana-sized power budget.Clinical labeled data is brutal to get. But continuous glucose traces, fetal monitoring strips, ICU telemetry: oceans of unlabeled sequence mostly discarded. Self-supervised pretraining on one modality turns 1,000 labels into 50,000.Kids also do not just compute fancier stats on confounded data. They intervene. That is the thing most clinical AI skips entirely. A causal layer that flags when observation cannot answer the question is worth more than another model trained on claims exhaust.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: How Midjourney’s 60-second full-body ultrasound scanner became a LinkedIn fever dream & what the Butterfly chip deal, the wellness-lane FDA play & overdiagnosis math tell healthcare investors 21.06.2026 10min

  Midjourney’s scanner went viral. The most-shared posts claimed its AI rebuilds your scan in real time. The company said there is no AI in the scanner at all. The feed inverted the most important fact.The imaging runs on Butterfly Network’s chip, 40 modules per prototype, under a deal worth up to $74M over 5 years. BFLY jumped 52-56% in a day. The headline said Midjourney. The business story is Butterfly.Current prototype: ~20 min, not 60 sec. About a dozen people scanned. Team of roughly 9. Sixty seconds is the goal. MRI comparison is launch-deck framing, not a published result.The company is launching under FDA general-wellness positioning, same lane Prenuvo and Ezra use. No diagnostic claims, no diagnostic clearance. The moment they claim it finds disease, the regulatory burden changes entirely.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: An Embedded-Expert Alternative to Benefits Consultants: How Self-Insured Employers Can Reclaim Their Own Claims Data, Sidestep Predatory TPA & PBM Contract Terms & Stop Paying for Conflict 18.06.2026 9min

  A self-funded employer spending $50M/yr on health claims often cannot produce its own claims data. The TPA holds it and charges for access. The employer is the fiduciary. This is the baseline absurdity.The contracts make it worse. TPA shared-savings fees run 20-30% of repricing. Audit rights are written to find nothing. Data ownership clauses say the TPA owns data the employer paid to generate.The benefits consultant is supposed to fix this. Except a large share of consultant pay comes from carriers and PBMs through overrides and retention bonuses the employer cannot see.The 2021 Consolidated Appropriations Act banned gag clauses and required broker compensation disclosure. The FTC has filed against the big three PBMs. ERISA fiduciary suits are targeting employers who cannot produce their own plan documents.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe
• 
  Part I: When the Rockets and the Robots Go Public: What the SpaceX, Anthropic & OpenAI IPOs Will Do to the Listing Market & Which Health & Life Sciences Companies Get to Ride the Next Hype Cycle 16.06.2026 11min

  SpaceX at $1.77T. Anthropic near $965B. OpenAI targeting $1T. Three filings just warped the entire listing market, including for healthcare.80% of global VC went to AI in Q1 2026. Four names took $188B of a record $300B quarter. Every healthcare company was fighting over the scraps.A trillion-dollar IPO does not compete with a $1B health tech float. It makes a $1B float invisible to generalist investors, for better or worse.The real signal is not the IPO calendar. If late-stage private rounds clear at flat-to-up valuations, the listing window is opening. Confidence flows backward.Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.onhealthcare.tech/subscribe